TheEdgeResearch
Home / Stocks / ALPS

Alps Group Inc (ALPS)

NASDAQ Healthcare Biotechnology
$0.40 ▼ -1.00%
Market Cap
$65.9M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.06
52-Wk Range
0.229-12.01
CEO
Seng Kong Tham
Country
MY
Currency
USD

Alps Group Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Kuala Lumpur, WP, MY. The stock last traded at $0.40, down 1.00% on the session, giving a market capitalisation of $65.9M. On trailing twelve-month figures it carries a trailing P/E of -0.43, a net margin of 0.0%. Its beta of -0.06 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.43
Price / Sales
0.00
Price / Book
-0.48
EV / EBITDA
-36.95
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.19
Current ratio
0.36
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
93
IPO date
2025-10-31
Headquarters
Kuala Lumpur, WP, MY
About Alps Group Inc

Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge therapeutic solutions. The organization is committed to cultivating a just and balanced healthcare system, ensuring broad availability of early detection, disease prevention, and individualized treatment approaches.

Comparable companies

Alps Group Inc is most often compared with the following Healthcare names:

ARGYFBNRGCHKREDBLGIPRGRNTHGTXUINDOOKYO
More research on ALPS
ALPS technical analysis ALPS TheEdge Score Compare against peers
Open full interactive analysis & DCF →